We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Urinary RNA Assay May Replace Needle Biopsy for Detection of Kidney Transplant Rejection

By LabMedica International staff writers
Posted on 17 Mar 2014
Print article
Determination of mRNA signatures in urine samples may replace needle biopsy for diagnosing kidney dysfunction following transplant surgery.

Investigators at Weill Cornell Medical College (New York, NY, USA) measured absolute levels of 26 pre-specified mRNAs in urine samples collected from kidney graft recipients at the time of needle biopsy for acute allograft dysfunction and investigated whether differential diagnosis of acute graft dysfunction would be feasible using urinary cell mRNA profiles. They profiled 52 urine samples from 52 patients with biopsy specimens indicating acute rejection (26 acute T cell–mediated rejections and 26 acute antibody-mediated rejections) and 32 urine samples from 32 patients with acute tubular injury without acute rejection.

Results of stepwise discriminant mRNA analysis identified a linear combination of mRNAs for CD3epsilon, CD105, TLR4, CD14, complement factor B, and vimentin that distinguished acute rejection from acute tubular injury. Among patients diagnosed with acute rejection, a similar statistical approach identified a linear combination of mRNAs for CD3epsilon, CD105, CD14, CD46, and 18S rRNA that distinguished T cell–mediated rejection from antibody-mediated rejection.

“Using statistical methods we have combined the mRNAs to yield a diagnostic signature,” said senior author Dr. Thangamani Muthukumar, assistant professor of medicine at Weill Cornell Medical College. “Our study shows that when the creatinine level is elevated in the blood of a kidney transplant recipient, use of our urine test would differentiate the common causes of kidney dysfunction that led to the elevation in creatinine, hence benefiting many patients by allowing them to avoid the need for an invasive needle biopsy.”

The study showing the correspondence between mRNA signatures and needle biopsy results was published in the March 7, 2014, online edition of the Journal of the American Society of Nephrology.

Related Links:

Weill Cornell Medical College


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.